Forgot your password?

Forgot your username?

database > company
GlobeImmune
Biotech Specialty Pharma
1450 Infinite Drive
Louisville, CO 80027 USA
phone:303.625.2700
fax:303.625.2710
Symbol Private
Founded 1995
Employees 54
www.globeimmune.com
Research Sector Biotech Specialty Pharma
Summary Description
Developing vaccines to treat human diseases such as HIV and cancer.
Management
Kirk Christoffersen, MBA, Senior Director Corporate Development; Claire Coeshott, Ph.D., Director, Imunology; Jeffrey Dekker, Senior Director, Finance & Controller; April Duffey, SPHR, Senior Director, Human Resources; John Ferraro, MBA, CCRA, Senior Director, Clinical Operations
Keywords
saccharomyces, tarmogens, globeimmune, immune, lymphocytes

Comment | Printable Version | Modify profile |
Updated: May 16, 2011

Description
GlobeImmune Inc.'s mission is to revolutionize healthcare through its proprietary vaccine technologies. The Company is designing vaccines with the unprecedented ability to prevent and treat human diseases such as HIV and cancers, leading to higher quality of life and lower overall healthcare costs.
Products / Services
The company's lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. The company's lead infectious disease program, GI-5005, is a Tarmogen for the treatment of chronic hepatitis C infection (HCV). GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV.
Technology / Differentiation
Tarmogens are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein targets that stimulate the immune system against diseased cells. Tarmogens are avidly taken up by the cells that activate the immune system called antigen presenting cells, to stimulate so called "killer T cells" directed against the desired target.


2012-02-07-490